$1,000 in Pfizer (PFE) Stock 3 Years Ago? Here’s the Brutal Truth About Your Portfolio Today

Pfizer’s Rollercoaster Ride: How the Pharma Giant Rewarded—or Wrecked—Your Investment

Three years ago, Pfizer was the darling of pandemic plays. Now? The hangover hits hard.

The Numbers Don’t Lie

While Wall Street analysts were busy high-fiving over vaccine revenue, PFE stock quietly bled out. That $1,000 investment? Let’s just say you’re not retiring on it.

Big Pharma’s Reality Check

Post-COVID demand cliffs crushed the party. Patent expirations loomed. And shareholders? Left holding the bag while executives cashed out—classic pharma maneuver.

Silver Linings for the Delusional

Sure, the dividend’s still there… for now. But in an era where Bitcoin ETFs outperform blue chips? Ouch.

Final Verdict: Should’ve YOLO’d into crypto instead—at least those losses come with memes.

Image source: Getty Images.

Some investors have been disappointed in Pfizer when they've compared recent results to those from the past. But those past years were exceptional boom years thanks to Pfizer's COVID-19 vaccine and Paxlovid COVID-19 treatment. Those were in great demand, but demand has fallen. Others worry because some of Pfizer's big sellers, such as Eliquis, Ibrance, Inlyta, Xeljanz, Xtandi, and Vyndaqel, are coming off patent protection in the next few years. Pfizer has been planning for that, and investing in its pipeline, which features more than 100 active programs -- many of which are in oncology. Pfizer has also been getting additional approvals for its drugs, and it has been cutting its costs in an effort to boost profitability.

Finally, Pfizer is a dividend-paying stock, with a whopping recent dividend yield of 7%. So as you invest in Pfizer and wait for its investments to pay off, you'll be rewarded.